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Abstract: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors 
worldwide. The major etiologies and risk factors for HCC development are well deﬁ  ned and 
some of the steps involved in hepatocarcinogenesis have been elucidated in recent years. 
Therapeutic options that can be applied in curative or palliative intention are available and are 
dependent on the HCC stage. The therapeutic options fall into ﬁ  ve main categories: (1) surgical 
interventions, including tumor resection and liver transplantation, (2) percutaneous interventions, 
including ethanol injection and radiofrequency thermal ablation, (3) transarterial interventions, 
including embolization and chemoembolization, (4) radiation therapy, and (5) drugs as well as 
gene and immune therapies. Until recently, no therapy existed for patients with advanced HCC. 
In 2007 a multikinase inhibitor (sorafenib) showed for the ﬁ  rst time a signiﬁ  cant increase in 
overall survival in patients with advanced HCC. Furthermore, several other agents that target 
different factors of hepatocarcinogenesis (eg, epidermal growth factor, insulin-like growth 
factors, hepatocyte growth factor, vascular endothelial growth factor, ﬁ  broblast growth factor, 
platelet-derived growth factor, and the transforming growth factors-α and -β), have emerged 
and been tested in clinical trials. This review gives an overview of the current therapeutic 
strategies and their clinical impact.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors world-
wide (Okuda 2000; Bruix et al 2001, 2004; Befeler and Di Bisceglie 2002; Bruix and 
Llovett 2002; Llovet et al 2003, 2004; El-Serag 2004; Fattovich et al 2004; Kiyosawa 
et al 2004; Serman and Klein 2004) and has been reviewed recently (Sherman and 
Klein 2004; Bruix and Sherman 2005; Marrero 2006; El-Serag and Rudolph 2007; 
Kulik 2007). The incidence ranges from 10 cases per 100,000 population and year 
in North America and Western Europe to 50–150 cases per 100,000 population and 
year in parts of Africa and Asia where HCC is responsible for a large proportion of 
cancer deaths. However, a rise in the incidence of and mortality from HCC, most 
likely reﬂ  ecting the high prevalence of hepatitis C virus (HCV) infection, has also been 
observed in most industrialized countries (Defufﬁ  c et al 1998; El-Serag and Mason 
1999; El-Serag 2004; Capocaccia et al 2007; Taylor-Robinson et al 1997).
HCC etiologies and risk factors
The major etiologies of HCC are well deﬁ  ned (Table 1) and include, apart from 
the well known factors, overweight in men (Calle et al 2003), non-alcoholic fatty 
liver disease (NAFLD), and diabetes mellitus (El-Serag 2004). The HCC risk in 
patients with liver cirrhosis depends on the activity, duration, and the etiology of 
the underlying liver disease (Figure 1). Clinical and biological variables, eg, age, 
anti-HCV positivity, partial prothrombin time, and platelet count, enable further Biologics: Targets & Therapy 2008:2(3) 454
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indentiﬁ  cation of a subset of patients with the highest risk 
of HCC development (Thomas et al 2007). While patients 
with hepatitis e antigen (HBeAg) positive chronic hepatitis 
B virus (HBV) have a higher risk of HCC development 
(Yang et al 2002) and of early recurrence and poor survival 
after curative resection (Sun et al 1997) than anti-HBe 
positive patients, a recent study in Taiwanese patients 
showed that the HBV DNA concentration in serum (viral 
load) correlates with the HCC risk, independent of the 
HBeAg/anti-HBe status and the aspartate aminotransferase 
or alanine aminotransferase level (Chen et al 2006). Also, 
occult (anti-HBc positive only) and past HBV infection 
(anti-HBc and anti-HBs positive) carry higher HCC risk 
than healthy individuals (Yano et al 2002; Pollicino et al 
2004). For HCV infected patients, recently identiﬁ  ed viral 
risk factors for HCC development are genotype 1b (Bruno 
et al 2007) and amino acid substitutions in the HCV core 
region (Akuta et al 2007).
Importantly, coexistence of etiologies, eg, HBV and 
HCV infection, HBV infection, and aﬂ  atoxin B1 exposure 
(Yu and Yan 2004; Ming et al 2002), HBV or HCV 
infection and alcohol use or diabetes mellitus (Hassan 
et al 2002), HCV infection and liver steatosis (Ohata et al 
2004), environmental factors, eg, alcohol (Morgan et al 
2004; Yu and Yan 2004; Marrero et al 2005b), as well as 
diabetes mellitus, obesity, and tobacco use (Calle et al 
2003; Caldwell et al 2004; El-Serag et al 2004; Marrero 
et al 2005b), has to be considered and further increases the 
relative risk of HCC development. Interestingly, coffee 
consumption appears to reduce the HCC risk (Bravi et al 
2007). HCC is generally more frequent in males than in 
females. Whether this is related to the protective effect of 
estrogens, as recently demonstrated in an animal model 
of chemical hepatocarcinogenesis (Naugler et al 2007), 
remains to be determined.
HCC pathogenesis
Some of the steps involved in the molecular pathogenesis 
of HCC have been elucidated in recent years (El-Serag 
and Rudolph 2007). As for most types of cancer, hepato-
carcinogenesis is a multistep process involving different 
genetic alterations that ultimately lead to malignant trans-
formation of the hepatocyte. While signiﬁ  cant progress has 
been made in recognizing the sequence of events involved 
in other forms of cancer, most notably in colorectal cancer 
and certain hematopoietic malignancies, the molecular 
contribution of the different factors and their interaction in 
hepatocarcinogenesis are still poorly understood. HCC is 
phenotypically (morphology, microscopy) and genetically 
very heterogenous, possibly in part due to the heterogeneity 
of etiologic factors implicated in HCC development, the 
complex functions of the liver cell, and the advanced stage 
at which HCC usually are becoming clinically symptomatic 
and diagnosed. Malignant transformation of hepatocytes 
may occur regardless of the etiologic agent through a path-
way of increased liver cell turnover, induced by chronic 
liver injury and regeneration in a context of inﬂ  ammation, 
immune response, and oxidative DNA damage. This may 
result in genetic alterations that cause activation of cellular 
oncogenes or inactivation of tumor suppressor genes (Dufour 
et al 2007), possibly in cooperation with genomic instability, 
including DNA mismatch repair defects and impaired 
chromosomal segregation, overexpression of growth and 
angiogenic factors, and telomerase activation (Ozturk 1999; 
Brechot 2004; Satayanarayma et al 2004; Suriawinata and 
Xu 2004; Yu and Yan 2004). Further, epigenetic modiﬁ  ca-
tions, eg, aberrant methylation, seem also to be involved in 
the molecular pathogenesis of human HCC (Calvisi et al 
Table 1 Major hepatocellular carcinoma etiologies
Chronic hepatitis B, C, and D
Toxins (eg, alcohol, tobacco, aﬂ  atoxins)
Hereditary metabolic liver diseases (eg, hereditary hemochromatosis, 
α-1-antitrypsin deﬁ  ciency)
Autoimmune hepatitis 
States of insulin resistance
  Overweight in males
 Diabetes  mellitus
   Non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver 
disease (NAFLD)
Figure 1 Hepatocellular carcinoma risk in liver cirrhosis from different etiologies.
Abbreviations: WD, Wilson´s disease; PBC, primary biliary cirrhosis, HH, hereditary 
hemochromatosis; HBV, hepatitis B virus infection; HCV, hepatitis C virus infection.
HCC risk (%) 
HH
HBV
Alcohol
HCV
WD    PBC
disease
70
60
50
40
30
20
10
0
80
LiverBiologics: Targets & Therapy 2008:2(3) 455
Hepatocellular carcinoma therapies
2007). Chronic hepatitis B, C, and D, alcohol, metabolic 
liver diseases such as hemochromatosis and α-1-antitrypsin 
deficiency, as well as NAFLD may act predominantly 
through this pathway of chronic liver injury, regeneration, 
and cirrhosis. Since the vast majority of HCC (70%–90%) 
develop in a cirrhotic liver, liver cirrhosis is a major clinical 
risk factor for HCC development. Most HCC occur after 
many years or decades of chronic hepatitis that provides the 
mitogenic and mutagenic environment that induces random 
genetic alterations which eventually result in the malignant 
transformation of hepatocytes and HCC development. While 
there is evidence that HBV and possibly also HCV may 
under certain circumstances play an additional direct role in 
the molecular hepatocarcinogenesis, aﬂ  atoxins have been 
shown to induce mutations of the p53 tumor suppressor 
gene, thus pointing to the contribution of an environmental 
factor to tumor development at the molecular level. Further, 
in a transgenic mouse model it has been shown that chronic 
immune-mediated liver cell injury without environmental or 
infectious agents is sufﬁ  cient to cause HCC (Nakamoto et al 
1998, 2002) and that inhibition of cytotoxic T lymphocyte-
induced apoptosis and chronic inﬂ  ammation by neutralization 
of the Fas ligand prevents HCC development in this model 
(Nakamoto et al 2002). In addition, also in a transgenic 
mouse model it has been demonstrated that NF-kappa B may 
be the link between inﬂ  ammation and HCC development 
(Balkwill and Coussens 2004; Pikarsky et al 2004). Finally, 
individual polymorphisms of drug metabolizing enzymes, 
eg, various cytochrome P450 oxidases, N-acetyltransferases, 
and glutathione-S-transferase, may contribute to the genetic 
susceptibility to HCC development (Chen and Chen 2002).
HCC staging
For HCC staging, seven systems have been proposed that 
address the extent and prognosis of the disease (Di Bisceglie 
2004; Talwalker and Gores 2004): the Okuda staging system 
(Okuda et al 1985), the TNM classiﬁ  cation and its modiﬁ  ca-
tion by the Union International Contre Cancer (UICC) (Leung 
et al 2002), the Barcelona Clinic Liver Cancer (BCLC) 
classiﬁ  cation (Llovet et al 1999), the Cancer of the Liver 
Italian Program (CLIP) score (Farinati et al 2000), the 
Japan Integrated Staging (JIS) score (Kudo et al 2004), the 
Groupe d’Etude de Traitement du Carcinoma Hepatocellu-
laire (GRETCH) score (Chevet et al 1999), and the Chinese 
University Prognostic Index (CUPI). The Okuda staging 
system is very effective for the identiﬁ  cation of a subgroup 
of patients (Okuda III) with a very poor prognosis who should 
be treated with best supportive care (BSC) only. The BCLC 
classiﬁ  cation appears especially useful for the selection of 
treatment options but has not been independently validated. 
The CLIP score was shown to be superior to the Okuda 
staging system but has not been systematically assessed in 
patients undergoing resection or liver transplantation. While 
a recent study indicates that the new prognostic JIS score is 
Figure 2 Key pathways in hepatocarcinogenesis and molecularly targeted agents currently under investigation in treatment of advanced HCC.   Adapted with permission 
from Gollob JA, Wilhelm S, Carter C, et al. 2006. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol, 
33:392–406. Copyright © 2006 Elsevier.
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superior to the CLIP score (Kudo et al 2004), a comparison of 
the staging systems in an American cohort revealed that the 
BCLC had the best independent predictive power (Marrero 
et al 2005a).
The natural course of the disease and the median survival 
of patients with HCC depend on the stage of the disease at 
the time of diagnosis. In patients with CLIP score 0 or Okuda 
stage I the median survival is in the range of 23–69 months, 
while in patients with CLIP score 3–5 or Okuda stage III 
median survival is only 1–14 months (Befeler and Di Bisce-
glie 2002). The staging system is clinically most important 
for the appropriate choice of the therapeutic strategy for 
individual patients. Cirrhotic patients developing a HCC 
during the last 5 years of surveillance survived longer than 
previously, due to improved management of the tumor and 
of the complications of cirrhosis (Sangiovanni et al 2004). 
Importantly, however, in a population-based study in the US 
underutilization of potentially curative therapies even among 
patients with favorable HCC features is a problem that needs 
to be addressed (El-Serag et al 2006).
Current therapeutic strategies 
for HCC
Current therapeutic strategies for HCC can be devided into 
established therapies such as surgical interventions (tumor 
resection and LTx), percutaneous interventions (ethanol 
injection, radiofrequency thermal ablation), transarterial 
interventions (embolization, chemoperfusion, or chemoem-
bolization), and experimental strategies such as radiation 
therapy and drugs, including gene and immune therapy. 
Potentially curative therapies are tumor resection, LTx, 
and percutaneous interventions that can result in complete 
responses and improved survival in a high proportion of 
patients. In selected cases transarterial interventions result 
in palliation with, in some cases, good response rates and 
improved survival. Until recently, for patients with advanced 
HCCs no therapy was available that prolonged overall sur-
vival (OS), indicating the need for new targeted-therapies. In 
2007 Sorafenib, a multikinase inhibitor, showed an increase 
of overall survival in patients with unresectable HCC. Besides 
this agent, various different molecules have been engineered 
that are currently tested in various tumors including HCC. 
These targeted therapies are reviewed below.
Potential targets for HCC therapies
Growth factors, their related receptors, and downstream 
signaling pathways play a major role in the development and 
maintenance of various cancers including HCC and are of 
signiﬁ  cant interest for future therapeutic approaches. During 
fetal life, a large number of growth factors including the 
epidermal growth factor (EGF), insulin-like growth factors 
(IGFs), the hepatocyte growth factor (HGF), the vascular 
endothelial growth factor (VEGF), the ﬁ  broblast growth 
factor (FGF), the platelet-derived growth factor (PDGF), and 
the transforming growth factors-α and -β (TGF-α, TGF-β) 
are produced in the liver. Their secretion declines or shuts 
down in an adult liver; however, when liver regeneration 
is required after injury or damage (Diehl 2002; Duncan 
2003), particularly growth factors such as EGF, TGF-α, 
IGFs, and VEGF can be upregulated by normal hepatocytes. 
This normally transient upregulation is dysregulated in 
the chronic injured liver leading to sustained mitogenic/
oncogenic signaling, thereby playing an important role in 
hepatocarcinogenesis.
Furthermore, members of the FGF and PDGF families 
play important roles in promoting liver ﬁ  brosis and HCC 
growth (Ogasawara et al 1996; Campbell et al 2005). Like 
HGF, these growth factors are produced and released from 
non-hepatocyte sources such as activated hepatic stellate 
cells, myoﬁ  broblasts, endothelial cells, Kupffer cells, and 
bile duct epithelia and do also contribute to hepatocarcino-
genesis.
Among the most critical cellular signaling pathways 
that support hepatocarcinogenesis are the receptor tyrosine 
kinase-activated pathways which include the rat sarcoma/rat 
sarcoma-activated factor (raf)/mitogen activated protein 
kinase/extracellular regulated kinase kinase/extracellular 
regulated kinase pathway (Ras/Raf/MEK/ERK), the Janus 
kinase/signal tranducers and activator of transcription 
pathway (JAK/STAT)s, and the phosphatidylinositide 3 
kinase/protein kinase B (AKT)/mammilian target of rapa-
mycin pathway (PI3K/AKT/mTOR) (Hopfner et al 2008; 
Zhu 2008).
These factors represent potential therapeutic targets in 
HCC treatment (Table 2). A selection of agents currently 
in the development and/or testing stages for the clinical 
application in targeted HCC treatment is summarized in the 
following section.
Anti-EGFR therapies
The expression of several EGF family members, speciﬁ  cally 
EGF, TGF-α, and heparin binding-EGF, as well as the 
EGFR, has been described in several HCC cell lines and in 
tissue. Multiple strategies to target EGFR signaling pathways 
have been developed, and two classes of anti-EGFR 
agents display antitumor activity in cancer: monoclonal Biologics: Targets & Therapy 2008:2(3) 457
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antibodies (eg, cetuximab), which competitively inhibit 
extracellular endogenous ligand binding, and small 
molecules, which inhibit the intracellular TK domain (eg, 
geﬁ  tinib, erlotinib).
While in vitro and in vivo studies with these agents have 
been shown to inhibit proliferation of HCC and metastasis 
formation, only a few clinical studies have been conducted 
so far. Two phase 2 clinical studies have evaluated the safety 
and efﬁ  cacy of erlotinib given at a dose of 150 mg daily in 
patients with advanced HCC. In the study by Philip et al 
(2005), 39% of patients had a partial response, and 32 had 
stable disease at 6 months. Median OS was 13 months. In 
a study by Thomas et al (2007), 43% of patients achieved 
progression-free survival (PFS) at 16 weeks. Median OS was 
25.0 weeks. Another compound, geﬁ  tinib, given at 250 mg 
daily was examined in a single-arm phase 2 study. Thirty-
one patients were recruited for the study (O’Dwyer et al 
2006). One patient had a partial response, and 7 patients had 
stable disease. Median PFS was 2.8 months, and the median 
OS was 6.5 months. Lapatinib, a selective dual inhibitor 
of both EGFR and HER-2/NEU TKs, also demonstrated 
modest activity in HCC in a preliminary report (Ramanathan 
et al 2006).
Cetuximab was tested in two studies in patients with 
advanced HCC. Zhu et al (2007) enrolled 30 patients with 
advanced HCC. Five patients had stable disease, median 
OS was 9.6 months, and the median PFS was 1.4 months. 
Gruenwald et al (2007) reported their experience of cetux-
imab in a similarly designed study and observed no responses 
in 27 patients; the median time to progression for all patients 
was 8 weeks.
The combination of cetuximab with GEMOX was 
evaluated in a phase 2 study (Louaﬁ   et al 2007). Forty-three 
patients were enrolled and 35 patients were available for 
efﬁ  cacy analysis with a response rate of 23%.
Currently, further anti-EGFR-based approaches are 
being tested in clinical trials, especially in combination with 
either conventional cytostatics or with other targeted agents 
(Heuther et al 2005a, b; Moore et al 2005; Bourhis et al 2006) 
in order to block several carcinogenic pathways.
Antivascular endothelial growth 
factor/vascular endothelial growth 
factor receptor agents
HCCs are tumors with high vascular architecture. VEGF is 
a key factor in tumor angiogenesis and high levels of VEGF 
have been associated with the HCC grade and clinically with 
inferior OS (Chao et al 2003; Jeng et al 2004; Poon et al 
2004). Therefore, the inhibition of angiogenesis represents 
a potential and promising therapeutic target in HCC. Beva-
cizumab, a humanized murine monoclonal anti-VEGF anti-
body, alone or in combination with standard chemotherapy 
has become standard treatment in several human cancers (eg, 
colon cancer). Studies with bevacizumab monotherapy and 
in combination with other agents have been performed in 
patients with advanced HCC. Most of the trials were phase 2 
studies with encouraging results for PFS and OS. Of interest 
is the study by Thomas et al (2007). In this phase 2 study, 
bevacizumab at a dose of 10 mg/kg intravenously once every 
14 days and erlotinib at a dose of 150 mg orally daily was 
given to patients with advanced HCC (Thomas et al 2007). 
Thirty-four patients were eligible for the efﬁ  cancy analysis: 
1 patient had a conﬁ  rmed complete response (CR), and 6 
patients had a partial response (PR), for a 21% response 
rate. Median PFS was 9 months, and median OS 19 months. 
However, these promising results have to be conﬁ  rmed in a 
randomized controlled study.
In terms of safety and tolerability, despite the initial 
safety concerns for bevacizumab use in patients with liver 
Table 2 Selection of agents for targeted therapy in hepatocellular 
carcinoma
Name Target Current status
Geﬁ  tinib EGFR phase 2 study (O’Dwyer et al 
2006)
Erlotinib EGFR phase 2 study (Philip et al 
2005; Thomas et al 2007)
Lapatanib EGFR phase 2 study (Ramanathan 
et al 2006)
Cetuximab EGFR phase 2 study (Gruenwald et al 
2007 Louaﬁ   et al 2007; Zhu 
et al 2007)
Bevacizumab VEGF phase 1/2 study (Schartz et al 
2006 Thomas et al 2007)
Sorafenib c-Raf1, B-Raf, 
VEGFR PDGFR
phase 3 study (Llovet et al 
2007)
Sunitinib PDGFR, VEGFR, 
c-KIT, FLT-3
phase 2 study (Faivre et al 
2007; Zhu et al 2007)
Vatalanib VEGFR, PDGFR, 
c-KIT
phase 1 study (Koch et al 
2005)
Cediranib VEGFR phase 2 study (Alberts et al 
2007)
Rapamycin mTOR phase 1/2 study (Sahin et al 
2004; Rizell et al 2005)
Everolimus mTOR phase 1/2 study (Sahin et al 
2004; Rizell et al 2005)
Bortezomib proteasome Phase 1/2 study (Hegewisch-
Becker et al 2004)Biologics: Targets & Therapy 2008:2(3) 458
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cirrhosis and portal hypertension, in particular the risks for 
gastrointestinal bleeding and thrombosis, the most common 
bevacizumab-related side effects were hypertension, 
bleeding, and proteinuria, that were generally well managed 
(Schwartz et al 2006).
In addition, several agents that inhibit the tyrosine 
kinase activity of VEGFR have been synthesized. PTK787/
ZK222584 (vatalanib) is an oral angiogenesis inhibitor 
that targets all known VEGFR TKs. In an open-labeled, 
multicenter, phase 1 study the safety, tolerability, and phar-
macokinetic proﬁ  le of PTK787 with a daily dose between 
750 mg to 1250 mg was analyzed in patients with unresect-
able HCC (Koch et al 2005). 750 mg daily was deﬁ  ned as 
maximal tolerated dose; however, in terms of efﬁ  cacy no 
complete response or partial response was observed. Fifty 
percent of the analyzed patients had stable disease and 50% 
had progressive disease.
Another potent, oral, pan-VEGFR TK inhibitor with 
activity against PDGFRs and c-Kit is AZD2171 (cediranib). 
So far, one phase 2 study by Alberts et al (2007) has studied 
the administration of AZD2171 (45 mg daily for a 28-day 
treatment cycle) in patients with advanced HCC. In terms 
of toxicity, 84% developed grade 3 toxicity mainly fatigue, 
hypertension, and anorexia.
A further encouraging approach is the use of dual-
targeting tyrosine kinase inhibitors, such as NVP-AEE788 or 
zactima (ZD6474). These molecules target both the VEGFRs 
and the EGFR. Recently, in in vivo studies of non-HCC tumor 
models (eg, colon, cholangiocarcinoma, NSCLC), NVP-
AEE788 showed signiﬁ  cant antitumor efﬁ  cacy based on the 
inhibition of tumor cell proliferation by blocking hepatoma 
EGFR and angiogenesis by blocking endothelial VEGFR. 
Nevertheless, an evaluation of this interesting observation 
in clinical trials is warranted (Heymach 2005; Busby et al 
2006; Wiedmann et al 2006; Younes et al 2006.
Multi-kinase inhibition
Hepatocarcinogenesis is a complex process involving 
various, diverse signaling pathways. Therefore, molecu-
larly targeted agents that interact with multiple signaling 
pathways/effectors appear to be very attractive in the treat-
ment of patients with HCC. The novel bi-aryl urea sorafenib 
(Nexavar®), an orally available multi-kinase inhibitor, targets 
kinases of wild-type B-Raf, mutant V559EB-Raf and C-
Raf, thereby blocking tumor growth. In addition, sorafenib 
inhibits receptor tyrosine kinases involved in angiogenesis, 
including human VEGF receptors-2 and -3 (VEGFR-2/-3) 
and PDGF-βR.
Sorafenib has been tested for the treatment of advanced 
HCC. In a phase 2 trial 137 patients with advanced, inoper-
able HCC, sorafenib (400 mg bid) induced a partial response 
in 2.2%, a minor response in 5.8% and a stable disease (SD) 
in 34% of patients (Abou-Alfa et al 2006). The median time 
to progression (TTP) was 4.2 months, and the median OS 
was 9.2 months. Sorafenib was fairly well tolerated. Grade 
3 and 4 drug-related toxicities were fatigue (9.5%), diarrhea 
(8%), and hand-foot skin reaction (5.1%). Interestingly, in an 
analysis of a subgroup of treated patients (n = 33), pretreat-
ment tumor phosphorylated ERK (pERK) levels were cor-
related with the TTP. Patients with an intense pERK staining 
in their tumors survived longer, suggesting that inhibition 
of the Raf/MEK/ERK pathway is central to sorafenib’s 
mode of anti-tumor action in HCC (Fattovich et al 2004). 
Whether this generally holds true for HCC remains to be 
determined. In other tumor entities the antineoplastic potency 
of sorafenib appears to be mainly due to its antiangiogenic 
activity (Wilhelm et al 2004; Liu et al 2006).
Based on the encouraging, positive results of this phase 
2 trial, a randomized, double-blinded, phase 3 trial with 602 
patients with advanced HCC was initiated. An evaluation of 
this international study (Sorafenib HCC Assessment Ran-
domized Protocol [SHARP]) led to discontinuation, as the 
HCC patients treated with sorafenib achieved a signiﬁ  cant 
survival beneﬁ  t over the placebo-treated controls. The data 
of the analysis were presented at the ASCO meeting in 2007 
and showed that median OS in the sorafenib-treated arm 
was 10.7 months vs 7.9 months in the control arm (Llovet 
et al 2007). Of note, the median TTP was 5.5 months in the 
sorafenib arm vs 2.8 months in the control arm. The toxicity 
proﬁ  le of this trial was comparable with that of the phase 
2 trial. Based on these ﬁ  ndings, sorafenib represents the 
ﬁ  rst agent that has shown improved OS beneﬁ  ts in patients 
with advanced HCC and has recently gained accelerated 
approval by the FDA for the treatment of advanced unre-
sectable HCC.
Another interesting multikinase inhibitor is sunitinib 
(Sutent®). It is a small molecule that inhibits members of 
the split-kinase domain family of receptor TKs (RTKs) 
including VEGFR types 1 and 2 (fms-related TK 1 [FLT1] 
and the FLK1 kinase insert domain receptor [FLK1/KDR]); 
PDGFR-α and PDGFR-β, the stem cell factor receptor c-KIT, 
and the FLT3 and RET kinases (Pawson 2002; Mendel et al 
2003; Arora et al 2005). In vitro studies with various tumor 
cell lines have shown that the antiangiogenic effects of suni-
tinib are mediated through VEGFR and PDGFR. Clinically, 
sunitinib has good oral bioavailability and is approved for Biologics: Targets & Therapy 2008:2(3) 459
Hepatocellular carcinoma therapies
the treatment of renal cell carcinoma and gastrointestinal 
stromal tumor.
Two independent phase 2 studies have examined the toler-
ability and efﬁ  cacy of sunitinib in patients with advanced HCC. 
In the study by Zhu et al (2007) patients with advanced HCC 
received sunitinib 37.5 mg once daily on a standard 4-weeks-
on/2-weeks-off regimen (6-week cycle). PFS was the primary 
endpoint. Median PFS in this trial was 4.1 months. A total 
of 26 patients were enrolled. Adverse events generally were 
manageable, and the most common adverse events included 
neutropenia, lymphopenia, thrombocytopenia, elevation of 
transaminases, fatigue, and skin rash. In the other phase 2 
study, sunitinib was administered at a dose of 50 mg daily in 
a 4-weeks-on/2-weeks-off regimen to patients with unresect-
able HCC (Faivre et al 2007). The primary endpoint of the 
study was the overall response rate according to RECIST 
criteria. Thirty-seven patients entered the trial, 1 patient had 
a conﬁ  rmed PR, and 39% of patients had SD. Grade 3 and 
4 toxicities included thrombocytopenia (43%), neutropenia 
(24%), central nervous system symptoms (24%), asthenia 
(22%), and hemorrhage (14%). Of interest, in a signiﬁ  cant 
number of patients sunitinib led to tumor necrosis in both stud-
ies; however, whether tumor necrosis is indeed correlated with 
clinical efﬁ  cacy remain to be deﬁ  ned in future studies.
mTOR inhibition
In vitro as well as preclinical in vivo data of HCC show 
that mTOR inhibition by rapamycin and its analogues (the 
cell cycle inhibitor-779 [CCI-779, temsirolimus], RAD001 
[everolimus]) an orally bioavailable derivative of rapamycin, 
AP23573) signiﬁ  cantly reduces HCC growth and improves 
survival primarily via antiangiogenic effects (Sahin et al 2004). 
A phase 2/3 trial evaluating everolimus for advanced HCC is 
currently starting to recruit patients (Rizell and Lindner 2005) 
(NIH, NCT00390195). In addition, the combination treatment 
of rapamycin and its analalogues with conventional cyto-
static drugs (eg, doxorubicin, vinblastine) has been shown to 
enhance the antitumoral potency compared with monotherapy 
with either doxorubicin or vinblastine in patients with HCC 
(Ribatti et al 2007; Semela et al 2007; Sieghart et al 2007). 
Therefore, the in vitro and in vivo data from other tumor enti-
ties suggest that mTOR inhibitors, including the rapamycin 
analogues CCI-779, RAD001 and AP23573, are promising 
combination agents for future cancer therapy.
Proteasome inhibition
Bortezomib (Velcade®) is a proteasome inhibitor, which blocks 
multi-ubiquitinated protein degradation by reversibly and 
competitively inhibiting the active site threonine residue of the 
26S proteasome (Mitsiades et al 2005). Antineoplastic activity 
of bortezomib has already beeen shown in several in vitro and 
in vivo studies (Brignole et al 2006; Baradari et al 2007; Hopf-
ner et al 2008) and has been recently approved for the treatment 
of mantle cell lymphoma. A phase 1/2 trial of bortezomib in 
patients with advanced HCC showed disease stabilization in 
some patients with good tolerability. In this study the authors 
recommend evaluating combination treatment strategies using 
bortezomib together with HCC-relevant cytostatics such as 
doxorubicin (Hegewisch-Becker et al 2004).
Conclusion
Agents that speciﬁ  cally target key molecules in carcinogen-
esis have emerged over the last decade. Of major interest 
are the growth factors and their receptors as well as their 
signaling pathways. The molecular targeting of these factors 
has become a promising approach for the effective treatment 
of various cancers, including hepatocellular carcinoma. The 
recent in vitro and in vivo ﬁ  ndings as well as the clinical 
trials clearly demonstrate that advanced HCC is no longer a 
tumor without speciﬁ  c medical treatment options. Sorafenib, 
a multi-kinase inhibitor, is the ﬁ  rst medication that is now 
approved for the treatment of patients with advanced HCC. 
However, several other promising new drugs are currently 
under investigation. Most probably, the combination of 
agents with different molecular targets as the growth factor 
receptor inhibitors, proteasome inhibitors, or cytostatics will 
improve the clinical response in patients with advanced HCC 
with tolerable and manageable side effects. Furthermore, the 
use of targeted therapies such as sorafenib, that are already 
approved for therapy in advanced HCC, might also improve 
HCC recurrence in patients who undergo resection, local 
ablation and transarterial chemoembolization, which is cur-
rently being tested in several studies.
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